Taiwanese Pharma Co. Says €142M Award Can't Be Enforced

By Caroline Simson · February 11, 2022, 10:12 PM EST

Taiwanese drug developer PharmaEssentia Corp. is fighting the enforcement of a €142 million ($161.1 million) arbitral award issued to Austrian pharmaceutical company AOP Orphan following an ill-fated deal to develop a...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Response

Case Information

Case Title

AOP Orphan Pharmaceuticals AG v. Pharmaessentia Corporation

Case Number

Court

Massachusetts

Nature of Suit

Other Statutes: Arbitration

Date Filed

November 19, 2020

Recent Articles By Caroline

May 07, 2025
Insulet Pursues EOFlow's Finances After $60M Ruling
April 07, 2025
Torrent Seeks Arbitration In Drug Commercialization Fight
March 17, 2025
BYD Affiliate Beats Megaclaim Over N95 Mask Deal
March 04, 2025
Meijer Says 1st Circ. Must Resolve Takeda Arbitration Order
February 19, 2025
Walgreens Says $1B COVID Testing Award Must Be Nixed
February 18, 2025
Novo Nordisk Queues Up $830M Suit Over Disappointing Drug
February 14, 2025
CVS Wins Arbitration In Medicare Fee Antitrust Suit
January 03, 2025
Enforcement Of $146M Chilean Hospital Award Sought In Conn.
December 11, 2024
AADI Enlists NY Court To Enforce Cancer Drug Award
November 15, 2024
Ariz. Judge Will Decide Proper Venue For CVS Antitrust Suit